Skeletal muscle SIRT1 and the genetics of metabolic health: Therapeutic activation by pharmaceuticals and exercise

Application of Clinical Genetics

Volumn 5, Issue , 2012, Pages 81-91

  Williams, Cameron B ^a   Gurd, Brendon J ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Exercise; Metabolic disease; Obesity; PGC 1a; Resveratrol; SIRT1

Indexed keywords

AGENTS AFFECTING METABOLISM; FATTY ACID; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RESVERATROL; SIRTUIN 1; SRT 1720; UNCLASSIFIED DRUG;

BIOGENESIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; EXERCISE; GENETIC REGULATION; HUMAN; INSULIN SENSITIVITY; INTERMETHOD COMPARISON; METABOLIC DISORDER; MOLECULAR PATHOLOGY; MUSCLE METABOLISM; MUSCLE MITOCHONDRION; NONHUMAN; OBESITY; PROTEIN CONTENT; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SKELETAL MUSCLE; THERAPY EFFECT; UPREGULATION;

EID: 84865822755     PISSN: 1178704X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ. 2007;176(8): S1-S13.
2. Kopelman PG. Obesity as a medical problem. Nature. 2000;404(6778): 635-643.
3. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32(9): 1431-1437.
4. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring). 2008;16(10): 2323-2330.
5. Zhang P, Zhang X, Brown J, etal. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3): 293-301.
6. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1): 4-14.
7. Kamei Y, Miura S, Suzuki M, etal. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem. 2004;279(39):41114-41123.
8. Muoio DM, Newgard CB. Obesity-related derangements in metabolic regulation. Annu Rev Biochem. 2006;75:367-401.
9. Dyson PA. The therapeutics of lifestyle management on obesity. Diabetes Obes Metab. 2010;12(11):941-946.
10. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002;51(10):2944-2950.
11. Kim JY, Hickner RC, Cortright RL, Dohm GL, Houmard JA. Lipid oxidation is reduced in obese human skeletal muscle. Am J Physiol Endocrinol Metab. 2000;279(5):E1039-E1044.
12. Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes. 2005;54(1):8-14.
13. Menshikova EV, Ritov VB, Ferrell RE, Azuma K, Goodpaster BH, Kelley DE. Characteristics of skeletal muscle mitochondrial biogenesis induced by moderate-intensity exercise and weight loss in obesity. J Appl Physiol. 2007;103(1):21-27.
14. Mootha VK, Lindgren CM, Eriksson KF, etal. PGC-1 alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267-273.
15. Patti ME, Butte AJ, Crunkhorn S, etal. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A. 2003;100(14):8466-8471.
16. Holloway GP, Bonen A, Spriet LL. Regulation of skeletal muscle mitochondrial fatty acid metabolism in lean and obese individuals. Am J Clin Nutr. 2009;89(1):455S-462S.
17. Lin J, Wu H, Tarr PT, etal. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature. 2002;418(6899):797-801.
18. Wu Z, Puigserver P, Andersson U, etal. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 1999;98(1):115-124.
19. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev. 2006;27(7):728-735.
20. Gerhart-Hines Z, Rodgers JT, Bare O, etal. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1 alpha. EMBO J. 2007;26(7):1913-1923.
21. Canto C, Auwerx J. PGC-1 alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol. 2009; 20(2):98-105.
22. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature. 2006;444(7121):868-874.
23. Philp A, Chen A, Lan D, etal. Sirtuin 1 (SIRT1) deacetylase activity is not required for mitochondrial biogenesis or peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1 alpha) deacetylation following endurance exercise. J Biol Chem. 2011;286(35): 30561-30570.
24. Herman KM, Craig CL, Gauvin L, Katzmarzyk PT. Tracking of obesity and physical activity from childhood to adulthood: the Physical Activity Longitudinal Study. Int J Pediatr Obes. 2009;4(4):281-288.
25. Boyko EJ, de Courten M, Zimmet PZ, Chitson P, Tuomilehto J, Alberti KG. Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance: a prospective study in Mauritius. Diabetes Care. 2000;23(9):1242-1248.
26. Holloway GP. Mitochondrial function and dysfunction in exercise and insulin resistance. Appl Physiol Nutr Metab. 2009;34(3):440-446.
27. Hickey MS, Weidner MD, Gavigan KE, Zheng D, Tyndall GL, Houmard JA. The insulin action-fiber type relationship in humans is muscle group-specific. Am J Physiol. 1995;269(1 Pt 1):E150-E154.
28. Simoneau JA, Colberg SR, Thaete FL, Kelley DE. Skeletal-muscle glycolytic and oxidative enzyme capacities are determinants of insulin sensitivity and muscle composition in obese women. FASEB J. 1995; 9(2):273-278.
29. Houmard JA, Egan PC, Neufer PD, etal. Elevated skeletal muscle glucose transporter levels in exercise-trained middle-aged men. Am J Physiol. 1991;261(4 Pt 1):E437-E443.
30. Simoneau JA, Veerkamp JH, Turcotte LP, Kelley DE. Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss. FASEB J. 1999;13(14):2051-2060.
31. Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol. 1999;277(6 Pt 1):E1130-E1141.
32. Asmann YW, Stump CS, Short KR, etal. Skeletal muscle mitochondrial functions, mitochondrial DNA copy numbers, and gene transcript profiles in type 2 diabetic and nondiabetic subjects at equal levels of low or high insulin and euglycemia. Diabetes. 2006;55(12):3309-3319.
33. Thyfault JP, Kraus RM, Hickner RC, Howell AW, Wolfe RR, Dohm GL. Impaired plasma fatty acid oxidation in extremely obese women. Am J Physiol Endocrinol Metab. 2004;287(6):E1076-E1081.
34. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol. 2002;90(5A): 11G-18G.
35. Holland WL, Knotts TA, Chavez JA, Wang L, Hoehn KL, Summers SA. Lipid mediators of insulin resistance. Nutr Rev. 2007;65(6 Pt 2): S39-S46.
36. Goodpaster BH, Theriault R, Watkins SC, Kelley DE. Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism. 2000;49(4):467-472.
37. Pan DA, Lillioja S, Kriketos AD, etal. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 1997;46(6): 983-988.
38. Timmers S, Schrauwen P, de Vogel J. Muscular diacylglycerol metabolism and insulin resistance. Physiol Behav. 2008;94(2):242-251.
39. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res. 2006;45(1):42-72.
40. Defronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3): 173-194.
41. Goodpaster BH, He J, Watkins S, Kelley DE. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab. 2001;86(12):5755-5761.
42. Samocha-Bonet D, Heilbronn LK, Lichtenberg D, Campbell LV. Does skeletal muscle oxidative stress initiate insulin resistance in genetically predisposed individuals? Trends Endocrinol Metab. 2010;21(2):83-88.
43. Schrauwen P, Hesselink MK. Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes. 2004;53(6): 1412-1417.
44. Furukawa S, Fujita T, Shimabukuro M, etal. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004; 114(12):1752-1761.
45. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84(21-22):705-712.
46. Wenz T, Rossi SG, Rotundo RL, Spiegelman BM, Moraes CT. Increased muscle PGC-1 alpha expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci U S A. 2009;106(48): 20405-20410.
47. Bruce CR, Thrush AB, Mertz VA, etal. Endurance training in obese humans improves glucose tolerance and mitochondrial fatty acid oxidation and alters muscle lipid content. Am J Physiol Endocrinol Metab. 2006;291(1):E99-E107.
48. Gibala MJ, Little JP, van Essen M, etal. Short-term sprint interval versus traditional endurance training: similar initial adaptations in human skeletal muscle and exercise performance. J Physiol. 2006;575(Pt 3): 901-911.
49. Ferrara N, Rinaldi B, Corbi G, etal. Exercise training promotes SIRT1 activity in aged rats. Rejuvenation Res. 2008;11(1):139-150.
50. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev. 2003;24(1):78-90.
51. Scarpulla RC. Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. Ann N Y Acad Sci. 2008;1147:321-334.
52. Lira VA, Benton CR, Yan Z, Bonen A. PGC-1 alpha regulation by exercise training and its influences on muscle function and insulin sensitivity. Am J Physiol Endocrinol Metab. 2010;299(2):E145-E161.
53. Holloszy JO. Regulation by exercise of skeletal muscle content of mitochondria and GLUT4. J Physiol Pharmacol. 2008;59(Suppl 7):5-18.
54. Gibala M. Molecular responses to high-intensity interval exercise. Appl Physiol Nutr Metab. 2009;34(3):428-432.
55. Wright DC, Han D, Garcia-Roves PM, Geiger PC, Jones TE, Holloszy JO. Exercise-induced mitochondrial biogenesis begins before the increase in muscle PGC-1 alpha expression. J Biol Chem. 2007;282(1): 194-199.
56. Perry CG, Lally J, Holloway GP, Heigenhauser GJ, Bonen A, Spriet LL. Repeated transient mRNA bursts precede increases in transcriptional and mitochondrial proteins during training in human skeletal muscle. J Physiol. 2010;588(Pt 23):4795-4810.
57. Handschin C, Rhee J, Lin JD, Tarr PT, Spiegelman BM. An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1 alpha expression in muscle. Proc Natl Acad Sci U S A. 2003;100(12):7111-7116.
58. Puigserver P, Rhee J, Lin J, etal. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPAR gamma coactivator-1. Mol Cell. 2001;8(5):971-982.
59. Jaeger S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1 alpha. Proc Natl Acad Sci U S A. 2007;104(29): 12017-12022.
60. Wright DC, Geiger PC, Han DH, Jones TE, Holloszy JO. Calcium induces increases in peroxisome proliferator-activated receptor gamma coactivator-1 alpha and mitochondrial biogenesis by a pathway leading to p38mitogen-activated protein kinase activation. J Biol Chem. 2007;282(26):18793-18799.
61. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1 alpha and SIRT1. Nature. 2005;434(7029):113-118.
62. Canto C, Gerhart-Hines Z, Feige JN, etal. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458(7241):1056-1060.
63. Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, Auwerx J. Sirtuins: the "magnificent seven, " function, metabolism and longevity. Ann Med. 2007;39(5):335-345.
64. Yang T, Sauve AA. NAD metabolism and sirtuins: metabolic regulation of protein deacetylation in stress and toxicity. AAPS J. 2006;8(4): E632-E643.
65. Flick F, Luscher B. Regulation of sirtuin function by posttranslational modifications. Front Pharmacol. 2012;3:29.
66. Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1 alpha. J Biol Chem. 2005;280(16):16456-16460.
67. Canto C, Jiang LQ, Deshmukh AS, etal. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab. 2010;11(3):213-219.
68. Banks AS, Kon N, Knight C, etal. SirT1gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 2008;8(4): 333-341.
69. Bordone L, Cohen D, Robinson A, etal. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell. 2007;6(6): 759-767.
70. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A. 2008;105(28):9793-9798.
71. Gurd BJ, Yoshida Y, McFarlan JT, etal. Nuclear SIRT1 activity, but not protein content, regulates mitochondrial biogenesis in rat and human skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 2011;301(1): R67-R75.
72. Lagouge M, Argmann C, Gerhart-Hines Z, etal. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha. Cell. 2006;127(6):1109-1122.
73. Zschoernig B, Mahlknecht U. SIRTUIN 1: regulating the regulator. Biochem Biophys Res Commun. 2008;376(2):251-255.
74. Sauve AA, Wolberger C, Schramm VL, Boeke JD. The biochemistry of sirtuins. Annu Rev Biochem. 2006;75:435-465.
75. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8(10):774-785.
76. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279(49):50754-50763.
77. Yang H, Yang T, Baur JA, etal. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell. 2007;130(6):1095-1107.
78. Costford SR, Bajpeyi S, Pasarica M, etal. Skeletal muscle NAMPT is induced by exercise in humans. Am J Physiol Endocrinol Metab. 2010; 298(1):E117-E126.
79. Anderson RM, Latorre-Esteves M, Neves AR, etal. Yeast life-span extension by calorie restriction is independent of NAD fluctuation. Science. 2003;302(5653):2124-2126.
80. Chabi B, Adhihetty PJ, O'Leary MF, Menzies KJ, Hood DA. Relationship between Sirt1 expression and mitochondrial proteins during conditions of chronic muscle use and disuse. J Appl Physiol. 2009;107(6):1730-1735.
81. Gurd BJ, Yoshida Y, Lally J, Holloway GP, Bonen A. The deacetylase enzyme SIRT1 is not associated with oxidative capacity in rat heart and skeletal muscle and its overexpression reduces mitochondrial biogenesis. J Physiol. 2009;587(Pt 8):1817-1828.
82. Kim J, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. Nature. 2008;451(7178):583-586.
83. Escande C, Chini CC, Nin V, etal. Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest. 2010;120(2):545-558.
84. Kim EJ, Kho JH, Kang MR, Um SJ. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell. 2007;28(2):277-290.
85. Nin V, Escande C, Chini CC, etal. Role of deleted in breast cancer 1 (DBC1) in SIRT1 activation induced by protein kinase A and AMP activated protein kinase. J Biol Chem. May 3, 2012. [Epub ahead of print.]
86. Gerhart-Hines Z, Dominy JE Jr, Blattler SM, etal. The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NAD+. Mol Cell. 2011;44(6):851-863.
87. Sasaki T, Maier B, Koclega KD, etal. Phosphorylation regulates SIRT1 function. PLoS One. 2008;3(12):e4020.
88. Nasrin N, Kaushik VK, Fortier E, etal. JNK1 phosphorylates SIRT1 and promotes its enzymatic activity. PLoS One. 2009;4(12):e8414.
89. Yang Y, Fu W, Chen J, etal. SIRT1sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol. 2007;9(11):1253-1262.
90. Liu X, Wang D, Zhao Y, etal. Methyltransferase Set7/9 regulates p53 activity by interacting with Sirtuin 1 (SIRT1). Proc Natl Acad Sci U S A. 2011;108(5):1925-1930.
91. Kornberg MD, Sen N, Hara MR, etal. GAPDH mediates nitrosylation of nuclear proteins. Nat Cell Biol. 2010;12(11):1094-1100.
92. Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Sinclair DA. Nicotinamide and PNC1govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature. 2003;423(6936):181-185.
93. Canto C, Auwerx J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab. 2009;20(7):325-331.
94. Feige JN, Lagouge M, Canto C, etal. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008;8(5):347-358.
95. Smith JJ, Kenney RD, Gagne DJ, etal. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst Biol. 2009;3:31.
96. Howitz KT, Bitterman KJ, Cohen HY, etal. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003; 425(6954):191-196.
97. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem. 2005;280(17):17187-17195.
98. Pacholec M, Bleasdale JE, Chrunyk B, etal. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 2010;285(11):8340-8351.
99. Chen S, Li J, Zhang Z, etal. Effects of resveratrol on the amelioration of insulin resistance in KKAy mice. Can J Physiol Pharmacol. 2012; 90(2):237-242.
100. Park SJ, Ahmad F, Philp A, etal. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148(3):421-433.
101. Milne JC, Lambert PD, Schenk S, etal. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007;450(7170):712-716.
102. Dai H, Kustigian L, Carney D, etal. SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem. 2010;285(43):32695-32703.
103. Baur JA, Pearson KJ, Price NL, etal. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117): 337-342.
104. Pearson KJ, Baur JA, Lewis KN, etal. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008;8(2):157-168.
105. Timmers S, Konings E, Bilet L, etal. Calorie restriction-like effects of 30days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612-622.
106. Crandall JP, Oram V, Trandafirescu G, etal. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci. January 4, 2012. [Epub ahead of print.]
107. Ghanim H, Sia CL, Korzeniewski K, etal. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab. 2011;96(5):1409-1414.
108. Haskell WL, Lee IM, Pate RR, etal. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007;39(8):1423-1434.
109. Gurd BJ. Deacetylation of PGC-1α by SIRT1: importance for skeletal muscle function and exercise-induced mitochondrial biogenesis. Appl Physiol Nutr Metab. 2011;36(5):589-597.
110. Benton CR, Wright DC, Bonen A. PGC-1 alpha-mediated regulation of gene expression and metabolism: implications for nutrition and exercise prescriptions. Appl Physiol Nutr Metab. 2008;33(5):843-862.
111. Koltai E, Szabo Z, Atalay M, etal. Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats. Mech Ageing Dev. 2010;131(1):21-28.
112. Li L, Pan R, Li R, etal. Mitochondrial biogenesis and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) deacetylation by physical activity: intact adipocytokine signaling is required. Diabetes. 2011;60(1):157-167.
113. Ljubicic V, Joseph AM, Adhihetty PJ, etal. Molecular basis for an attenuated mitochondrial adaptive plasticity in aged skeletal muscle. Aging (Albany, NY). 2009;1(9):818-830.
114. Suwa M, Nakano H, Radak Z, Kumagai S. Endurance exercise increases the SIRT1 and peroxisome proliferator-activated receptor gamma coactivator-1 alpha protein expressions in rat skeletal muscle. Metabolism. 2008;57(7):986-998.
115. Guerra B, Guadalupe-Grau A, Fuentes T, etal. SIRT1, AMP-activated protein kinase phosphorylation and downstream kinases in response to a single bout of sprint exercise: influence of glucose ingestion. Eur J Appl Physiol. 2010;109(4):731-743.
116. Little JP, Safdar A, Wilkin GP, Tarnopolsky MA, Gibala MJ. A practical model of low-volume high-intensity interval training induces mitochondrial biogenesis in human skeletal muscle: potential mechanisms. J Physiol. 2010;588(Pt 6):1011-1022.
117. Gurd BJ, Little JP, Perry CG. Does SIRT1 determine exercise-induced skeletal muscle mitochondrial biogenesis: differences between in vitro and in vivo experiments? J Appl Physiol. 2012;112(5): 926-928.
118. Dumke CL, Davis JM, Murphy EA, etal. Successive bouts of cycling stimulates genes associated with mitochondrial biogenesis. Eur J Appl Physiol. 2009;107(4):419-427.
119. Menshikova EV, Ritov VB, Toledo FG, Ferrell RE, Goodpaster BH, Kelley DE. Effects of weight loss and physical activity on skeletal muscle mitochondrial function in obesity. Am J Physiol Endocrinol Metab. 2005;288(4):E818-E825.
120. Goodpaster BH, Katsiaras A, Kelley DE. Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity. Diabetes. 2003;52(9):2191-2197.
121. Knowler WC, Barrett-Connor E, Fowler SE, etal. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
122. Laaksonen DE, Lindstrom J, Lakka TA, etal. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes. 2005;54(1):158-165.
123. Hawley JA, Gibala MJ. Exercise intensity and insulin sensitivity: how low can you go? Diabetologia. 2009;52(9):1709-1713.
124. Tjonna AE, Lee SJ, Rognmo O, etal. Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: a pilot study. Circulation. 2008;118(4):346-354.
125. Wolff E, Gaudlitz K, von Lindenberger BL, Plag J, Heinz A, Strohle A. Exercise and physical activity in mental disorders. Eur Arch Psychiatry Clin Neurosci. 2011;261(Suppl 2):S186-S191.
126. Pekmezi DW, Demark-Wahnefried W. Updated evidence in support of diet and exercise interventions in cancer survivors. Acta Oncol. 2011;50(2):167-178.
127. Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in chronic disease. Scand J Med Sci Sports. 2006;16(Suppl 1):3-63.
128. Warburton DE, Nicol CW, Bredin SS. Health benefits of physical activity: the evidence. CMAJ. 2006;174(6):801-809.